You are here
Qu Biologics’ Site Specific Immunomodulators Enhance Adoptive T cell Therapies in Solid Tumours
VANCOUVER, British Columbia, Nov. 05, 2018 (GLOBE NEWSWIRE) -- Qu Biologics Inc., a biopharmaceutical company developing Site Specific Immunomodulators (SSIs), a novel platform of immunotherapies designed to restore innate immune function, is pleased to announce that collaborative studies at Dartmouth College have demonstrated that SSIs substantially enhance adoptive cell therapies for the treatment of solid tumours in lung cancer models.
Adoptive T cell therapy, including CAR T cell therapy, has shown substantial benefit for the treatment of specific ‘liquid’ cancers (e.g., leukemias and lymphomas). However, adoptive T cell therapy has had limited success in solid tumors due to:
1. Poor infiltration of adoptive T cells into solid tumors
2. Immunosuppression in the tumor microenvironment
In collaborative research at Dartmouth College, T cell immunologist Dr. David Mullins demonstrated that SSIs substantially increased adoptive T cell infiltration into the targeted organ/solid tumors and substantially improved adoptive T cell cancer efficacy in lung cancer mouse models.
Dr. David Mullins, Associate Professor at Dartmouth, stated, “Tumour-induced suppression of T cell infiltration has been a significant roadblock for clinically-effective cell-based immunotherapy. We’re excited to find that SSIs may be a safe and effective approach that resets the tumour microenvironment to favor T cell recruitment and anti-tumour efficacy.” Dr. Hal Gunn, Qu Biologics’ CEO added, “This compelling data demonstrates that SSIs may overcome the well-known limitations of the application of adoptive T cell therapy for the treatment of solid tumors, thus, potentially expanding the application of transformative therapies to the 95%+ of cancers that are solid tumours.”
For more information about Qu Biologics and the science behind SSIs, please visit www.qubiologics.com.
About Qu Biologics
Qu Biologics is a clinical stage biotechnology company developing Site Specific Immunomodulators (SSI), a novel class of immunotherapies designed to stimulate an innate immune response in targeted organs to reverse the chronic inflammation underlying many important diseases including inflammatory bowel disease, cancer, inflammatory lung disease and arthritis. Qu has completed three Phase 2 studies in Crohn’s disease, ulcerative colitis and lung cancer.
Backed by a prestigious group of scientific advisors and board members, Qu Biologics is led by a management team that includes co-founder and CEO Dr. Hal Gunn, a physician and expert on the body’s immune response to chronic disease; and Chief Medical Officer Dr. Simon Sutcliffe, former CEO of the BC Cancer Agency and a distinguished clinician, scientist and leader in cancer control in Canada and internationally.
For more information regarding this press release, contact:
Hal Gunn, MD
Qu Biologics Inc.
Qu Biologics Inc. cautions you that statements included in this press release that are not a description of historical facts may be forward-looking statements. Forward-looking statements are only predictions based upon current expectations and involve known and unknown risks and uncertainties. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of release of the relevant information, unless explicitly stated otherwise. Actual results, performance or achievement could differ materially from those expressed in, or implied by, Qu Biologics’ forward-looking statements due to the risks and uncertainties inherent in Qu Biologics’ business including, without limitation, statements about: the progress and timing of its clinical trials; difficulties or delays in development, testing, obtaining regulatory approval, producing and marketing its products; unexpected adverse side effects or inadequate therapeutic efficacy of its products that could delay or prevent product development or commercialization; the scope and validity of patent protection for its products; competition from other pharmaceutical or biotechnology companies; and its ability to obtain additional financing to support its operations. Qu Biologics does not assume any obligation to update any forward-looking statements except as required by law.